公开(公告)号：EP4265638A1

公开(公告)日：2023-10-25

申请号：EP21905330.3

申请日：2021-10-29

申请人： Beijing Immunochina Pharmaceuticals Co., Ltd. ,  Shandong Jinsai Co., Ltd.

发明人： HE, Ting ,  QI, Feifei ,  LU, Xin-An ,  DING, Yanping ,  LIANG, Mengmeng

IPC分类号： C07K16/28 ,  C07K19/00 ,  C12N15/13 ,  C12N15/62 ,  C12N15/867 ,  C12N5/10 ,  A61K39/00 ,  A61P35/02

摘要： Provided in the present invention is a single-chain antibody scFv that specifically binds to CD123, including an amino acid sequence selected from SEQ ID NOs: 56, 57, 58, 59, 60 and 61. Also provided is a chimeric antigen receptor targeting CD123, including an amino acid sequence selected from SEQ ID NOs: 65, 66, 67, 68, 69 and 70. Further provided are a nucleic acid molecule encoding the scFv or chimeric antigen receptor, a vector and cell containing the nucleic acid molecule, and the use of the antibody, chimeric antigen receptor, nucleic acid molecule, vector or cell in the preparation of a drug for treating tumor expressing CD123.

公开(公告)号：EP4263606A1

公开(公告)日：2023-10-25

申请号：EP21831061.3

申请日：2021-12-17

申请人： OSE IMMUNOTHERAPEUTICS

发明人： POIRIER, Nicolas ,  MARY, Caroline ,  MORELLO, Aurore ,  SEITE, Margaux

IPC分类号： C07K16/28 ,  C07K14/54 ,  C07K14/55 ,  A61K38/20 ,  C12N15/62 ,  C12N15/13 ,  A61P35/00

公开(公告)号：EP4260872A1

公开(公告)日：2023-10-18

申请号：EP21903350.3

申请日：2021-12-06

申请人： National University Corporation Tokyo Medical and Dental University

发明人： OKAZAWA, Hitoshi

IPC分类号： A61K39/395 ,  A61P25/28 ,  C07K16/18 ,  C12N15/13

摘要： An object of the present invention is to provide an agent for preventing or treating frontotemporal lobar degeneration which does not cause noticeable adverse reactions and exhibits an excellent effect of preventing and treating frontotemporal lobar degeneration caused by different factors. In the present invention, a human monoclonal antibody that specifically binds to human HMGB1, which comprises heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, can be used as an agent for preventing or treating frontotemporal lobar degeneration.

公开(公告)号：EP4260870A1

公开(公告)日：2023-10-18

申请号：EP21901679.7

申请日：2021-12-07

申请人： Mie University

发明人： SHIKU, Hiroshi ,  AKAHORI, Yasushi ,  HIRATSUKA, Hiroyuki

IPC分类号： A61K39/395 ,  A61K48/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/30 ,  C07K19/00 ,  C12N5/10 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N15/12 ,  C12N15/13 ,  C12N15/62 ,  A61K35/17

摘要： An object is to provide a PRAME-binding molecule. This object is achieved by a PRAME-binding molecule comprising a heavy-chain variable region containing a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, and a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, and/or a light-chain variable region containing a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 9, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 10, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 11.

公开(公告)号：EP4257610A1

公开(公告)日：2023-10-11

申请号：EP22739046.5

申请日：2022-01-12

申请人： Bioheng Therapeutics Limited

发明人： ZHOU, Yali ,  CHEN, Gong ,  GUO, Tingting ,  JIANG, Xiaoyan ,  REN, Jiangtao ,  HE, Xiaohong ,  WANG, Yanbin ,  HAN, Lu ,  LI, Guokun ,  ZHANG, Jing ,  SUN, Huifang

IPC分类号： C07K16/30 ,  C12N15/13 ,  C12N15/63 ,  A61K39/395 ,  A61P35/00

摘要： Provided are an ROR1-targeting antibody, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with ROR1 expression.

公开(公告)号：EP4253411A1

公开(公告)日：2023-10-04

申请号：EP21896926.9

申请日：2021-11-23

申请人： Sanyou Biopharmaceuticals Co., Ltd.

发明人： TAN, Yongcong ,  LANG, Guojun ,  LIU, Chanjuan ,  YAN, Xintian

IPC分类号： C07K16/18 ,  C12N15/13 ,  G01N33/574 ,  A61K39/395 ,  A61P35/00

摘要： Provided are a molecule specifically binding to CLDN18.2, the molecule comprising an immunoglobulin single variable domain, a nucleic acid molecule encoding the molecule specifically binding to CLDN18.2, and an expression vector and a host cell for expressing the molecule specifically binding to CLDN18.2; further provided are a method for producing the molecule specifically binding to CLDN18.2 and use thereof for treating or preventing conditions associated with CLDN18.2.

公开(公告)号：EP4247854A1

公开(公告)日：2023-09-27

申请号：EP21894026.0

申请日：2021-11-19

申请人： Bliss Biopharmaceutical (Hangzhou) Co., Ltd.

发明人： XIA, Bing ,  KONG, Hao ,  CAO, Lixia ,  JIANG, Fangdun ,  ZHOU, Yuhong ,  WEI, Ziping

IPC分类号： C07K16/28 ,  C07K19/00 ,  C12N15/13 ,  C12N5/10 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  A61K47/68 ,  G01N33/574

公开(公告)号：EP4247848A1

公开(公告)日：2023-09-27

申请号：EP21895765.2

申请日：2021-11-22

申请人： Scout Bio, Inc.

发明人： BUSFIELD, Samantha J. ,  WILSON, Matthew J.

IPC分类号： C07K16/24 ,  G01N33/577 ,  C12N15/13

公开(公告)号：EP4242227A1

公开(公告)日：2023-09-13

申请号：EP22382225.5

申请日：2022-03-09

申请人： Consejo Superior De Investigaciones Científicas ,  Universidad de Las Palmas de Gran Canaria

发明人： FERNÁNDEZ HERRERO, Luis Ángel ,  CASASNOVAS SUELVES, José María ,  MARGOLLES AZPIAZU, Yago ,  NORIEGA FEBRERO, María de los Ángeles ,  GASTAMINZA LANDART, Pablo ,  GARAIGORTA DE DIOS, Urtzi ,  MARTÍN ACEBES, Miguel Ángel ,  SAIZ CALAHORRA, Juan Carlos ,  CORBERA SÁNCHEZ, Juan Alberto

IPC分类号： C07K16/10 ,  A61K39/395 ,  A61P31/14 ,  C12N15/13 ,  G01N33/569 ,  G01N33/577

摘要： The invention relates to a nanobody directed against the receptor binding domain (RBD) of spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to a fusion protein comprising said nanobody, and to a heavy chain antibody comprising two heavy chains, wherein each heavy chain comprises said fusion protein. The invention also relates to a bivalent construction comprising two nanobodies, wherein said two nanobodies are linked by a peptide bond. The invention also relates to a nucleic acid encoding the said nanobody, fusion protein or bivalent construction, to a vector comprising said nucleic acid, to a host cell comprising said nucleic acid or said vector, and to a pharmaceutical composition comprising said nanobody, fusion protein, heavy chain antibody or bivalent construction. The invention also relates to the medical uses of said nanobody, fusion protein, heavy chain antibody, bivalent construction or pharmaceutical composition for use in the treatment and/or prevention of an infection caused by SARS-CoV-2, and to a method for diagnosing an infection SARS-CoV-2 in a subject comprising contacting a sample from the subject with said nanobody, fusion protein, heavy chain antibody or bivalent construction.

公开(公告)号：EP4234579A1

公开(公告)日：2023-08-30

申请号：EP21882137.9

申请日：2021-10-22

申请人： Akeso Biopharma, Inc. ,  Akeso Pharmaceuticals, Inc.

发明人： LI, Baiyong ,  XIA, Yu ,  WANG, Zhongmin

IPC分类号： C07K16/28 ,  C12N15/13

摘要： An anti-CD73 antibody and the use thereof. The heavy chain variable region of the antibody comprises HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 15-17; and the light chain variable region of the antibody comprises LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 18-20.